title: Analysis of bacteremia after pancreatic transplantation with enteric drainage.
abstract: OBJECTIVE
  The objective of this study was to review the incidence, risk factors, and impact of bacteremia after pancreas transplantation (PTX).
  
  
  METHODS
  We performed a retrospective analysis of consecutive simultaneous kidney-pancreas transplantations (SKPTs) and solitary PTXs from January 2002 through April 2007. Positive blood cultures were correlated with other coexisting infections and parameters.
  
  
  RESULTS
  One hundred ten PTXs with enteric drainage included 80 SKPTs and 30 solitary PTXs. Mean follow-up was 32 months. Bacteremia occurred in 29 (26%) patients with 5 (17%) being recurrent; it was seen during the first month after transplantation in 13 (12%), between 1 and 3 months in 12 (11%), between 3 and 12 months in 3 (3%), and after the first year in 3 cases (3%). Typical organisms were as follows: MRSE, MSSE, Klebsiella, Escherichia coli, vancomycin-resistant enterococci (VRE), and Acinetobacteri. Bacteremia was associated with coexisting site infection in 20 cases (69%): deep abdominal wound (31%); line (31%); urinary tract (34%); and pulmonary (7%). Similar bacterial species in blood and a coexisting site occurred in 15 cases (52%). No correlation was seen with cytomegalovirus (CMV) infections. In the first year, bacteremia was associated with more acute rejection episodes (32% vs 17%; P = .09), surgical complications (54% vs 42%; P = .267), mortality (11% vs 4%; P = .15), and death-censored pancreatic (14% vs 9%; P = .39) and kidney (4% vs 0; P = .08) graft loss. Fewer patients with bacteremia received alemtuzumab compared with rATG induction (14% vs 39%; P = .04).
  
  
  CONCLUSIONS
  Bacteremias were common within 3 months of PTX. A significant number (39%) were multidrug resistant. The majority were accompanied by abdominal, urinary, or line infections. Bacteremias were associated with slightly higher incidences of rejection, mortality, and graft loss.
authors: Department of General Surgery, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina 27157, USA.
authors: R P
authors: RP
authors: Singh
authors: A C
authors: AC
authors: Farney
authors: J
authors: J
authors: Rogers
authors: E
authors: E
authors: Ashcraft
authors: L
authors: L
authors: Hart
authors: W
authors: W
authors: Doares
authors: E L
authors: EL
authors: Hartmann
authors: A
authors: A
authors: Reeves-Daniel
authors: P L
authors: PL
authors: Adams
authors: R J
authors: RJ
authors: Stratta
mesh_terms: D000328:Adult; D016470:Bacteremia / Q000453:epidemiology* / Q000209:etiology; D001419:Bacteria / Q000145:classification / Q000302:isolation & purification; D004322:Drainage / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology / Q000401:mortality; D016035:Pancreas Transplantation / Q000009:adverse effects* / Q000276:immunology / Q000401:mortality; D011168:Portal System; D012189:Retrospective Studies; D016019:Survival Analysis; D017741:Survivors
chemical_list: D007166:Immunosuppressive Agents